NO950201L - Hybrid oligonukleotidfosfortioater - Google Patents
Hybrid oligonukleotidfosfortioaterInfo
- Publication number
- NO950201L NO950201L NO950201A NO950201A NO950201L NO 950201 L NO950201 L NO 950201L NO 950201 A NO950201 A NO 950201A NO 950201 A NO950201 A NO 950201A NO 950201 L NO950201 L NO 950201L
- Authority
- NO
- Norway
- Prior art keywords
- hybrid
- hybrid oligonucleotide
- oligonucleotide phosphorothioates
- ribonucleosides
- phosphorothioates
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title abstract 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 title 1
- 239000002342 ribonucleoside Substances 0.000 abstract 2
- 102100034343 Integrase Human genes 0.000 abstract 1
- 101710203526 Integrase Proteins 0.000 abstract 1
- 101710163270 Nuclease Proteins 0.000 abstract 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000005549 deoxyribonucleoside Substances 0.000 abstract 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 abstract 1
Landscapes
- Saccharide Compounds (AREA)
Abstract
Hybride oligonukleotider med fosforotioat eller fosforoditioat internukleotidblndinger, og både deoksyribonukleosider og ribonukleosider eller 2'-substltuerte ribonukleosider er beskrevet. Slike hybride oligonukleosider har overlegende egenskaper når det gjelder dupleksdannelse med RNA, nuklease resistens og RNase H aktivering.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/918,239 US5652355A (en) | 1992-07-23 | 1992-07-23 | Hybrid oligonucleotide phosphorothioates |
| PCT/US1993/006884 WO1994002498A1 (en) | 1992-07-23 | 1993-07-22 | Hybrid oligonucleotide phosphorothioates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO950201D0 NO950201D0 (no) | 1995-01-19 |
| NO950201L true NO950201L (no) | 1995-01-19 |
Family
ID=26786893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO950201A NO950201L (no) | 1992-07-23 | 1995-01-19 | Hybrid oligonukleotidfosfortioater |
Country Status (1)
| Country | Link |
|---|---|
| NO (1) | NO950201L (no) |
-
1995
- 1995-01-19 NO NO950201A patent/NO950201L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO950201D0 (no) | 1995-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI950254A0 (fi) | Hybridi-oligonukleotidifosforotioaatteja | |
| TR199801581T2 (xx) | �ekerle de�i�tirilmi� bo�luklu oligon�kleotid'ler. | |
| EP0863911A4 (en) | ANTISENSE OLIGONUCLEOTID MODULATION OF raf GENE EXPRESSION | |
| HU9603277D0 (en) | Antisense oligonucleotide modulation of raf gene expression | |
| PL307025A1 (en) | Self-stabilising oligonucleotides | |
| ATE221914T1 (de) | Gegenläufige oligonukleotide mit hemmender wirkung auf tumorbildung | |
| AU4973899A (en) | Carbohydrate or 2'-modified oligonucleotides having alternating internucleoside linkages | |
| ATE162198T1 (de) | Oligonukleotid alkylphosphonothiate | |
| EP1340765A3 (en) | Inverted chimeric and hybrid oligonucleotides | |
| EP0977767A4 (en) | AMINOOXY MODIFIED OLIGONUCLEOTIDES | |
| DK0691980T3 (da) | 7-deazapurinmodifiderende oligonukleotider | |
| EP0804563A4 (en) | Antisense oligonucleotide generators | |
| NO973838L (no) | DNA-molekyler, deres fremstilling samt anvendelse ved genterapi | |
| EP0643720A4 (en) | Binding competent oligomers containing 2', 5' linkages. | |
| EP1044987A3 (en) | Gapped 2'-modified oligonucleotides | |
| MXPA02009627A (es) | Modificaciones genomicas cromosomicas selectivas con oligonucleotidos modificados de un solo filamento.. | |
| Clark | Antisense therapeutics in chronic myeloid leukaemia: the promise, the progress and the problems | |
| WO1999050409A9 (en) | Mixed-backbone oligonucleotides containing pops blocks to obtain reduced phosphorothioate content | |
| MX9700643A (es) | Oligonucleotidos modificados con 5'-ditio. | |
| Warzocha et al. | Antisense strategy: biological utility and prospects in the treatment of hematological malignancies | |
| IT1320168B1 (it) | Oligonucleotidi sintetici in grado di indurre il differenziamentoeritroide. | |
| Abdula | Silencing the code | |
| Dosanjh | Biophysical Studies of Triplex and Quadruplex DNA Systems | |
| NO950201D0 (no) | Hybrid oligonukleotidfosfortioater |